Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

39.98
+0.41001.04%
Post-market: 39.97-0.0100-0.03%19:54 EDT
Volume:7.60M
Turnover:304.35M
Market Cap:28.88B
PE:-85.06
High:40.97
Open:40.45
Low:39.50
Close:39.57
52wk High:42.50
52wk Low:14.50
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.11
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.83
PE(LYR):-74.04

Loading ...

Roivant Sciences Ltd: Topline Phase 3 Data in Niu and Phase 3 Study Initiation in Cs Are Expected in Second Half of Calendar Year 2026

THOMSON REUTERS
·
Apr 02

Roivant Announces Expansion of Brepocitinib Development Program With New Phase 2B/3 Trial in Lichen Planopilaris (Lpp) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (Ted)

THOMSON REUTERS
·
Apr 02

Roivant Sciences Ltd - Ted Study Patients Show Greater Proptosis Improvement After High-Dose Period

THOMSON REUTERS
·
Apr 02

Roivant director Meghan FitzGerald disposes of common shares worth $1.92 million

Reuters
·
Mar 31

S&P 500 Futures Climb In Premarket Trading; United Therapeutics, Alcoa Lead

Dow Jones
·
Mar 30

Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success

Simply Wall St.
·
Mar 29

BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis

Reuters
·
Mar 29

Roivant’s brepocitinib beats placebo in Phase 3 dermatomyositis trial, NEJM reports

Reuters
·
Mar 29

Roivant Sciences Ltd - FDA Grants Priority Review to Brepocitinib Nda With Pdufa Date in Q3 2026

THOMSON REUTERS
·
Mar 29

New England Journal of Medicine Publishes Positive Phase 3 Valor Trial Results of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Mar 29

Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?

Simply Wall St.
·
Mar 28

Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit

Reuters
·
Mar 23